The prevalence and mechanism of triclosan resistance in Escherichia coli isolated from urine samples in Wenzhou, China

Weiliang Zeng
  Wenzhou Medical University

Wenya Xu
  Wenzhou Medical University First Affiliated Hospital

Ye Xu
  Wenzhou Medical University First Affiliated Hospital

Wenli Liao
  Wenzhou Medical University First Affiliated Hospital

Yajie Zhao
  Wenzhou Medical University

Xiangkuo Zheng
  Wenzhou Medical University

Chunquan Xu
  Wenzhou Medical University First Affiliated Hospital

Tieli Zhou
  Wenzhou Medical University First Affiliated Hospital

Jianming Cao (✉ wzcjming@163.com)
  Wenzhou Medical University  https://orcid.org/0000-0002-9968-6721

Research

Keywords: Escherichia coli, Triclosan, Efflux pump, Resistance, fabI, Cross-resistance, Multidrug-resistance

DOI: https://doi.org/10.21203/rs.3.rs-24751/v2

License: ☇ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The widespread application of triclosan contributes to its residual deposition in urine, which provides an environment of long-term exposure to triclosan for the intestinal Escherichia coli. We determined the triclosan and antibiotic resistance characteristics of E. coli strains isolated from urine samples and further investigated the resistance mechanism and molecular epidemic characteristics of triclosan-resistant E. coli isolates. Methods: A total of 200 non-repetitive E. coli strains were isolated from urine samples and then identified. The minimum inhibitory concentrations (MICs) of triclosan and antibiotics, fabI mutation, efflux pump activity, the expression of 14 efflux pump encoding genes, and epidemiological characteristics were determined by the agar dilution method, polymerase chain reaction (PCR), carbonyl cyanide 3-chlorophenylhydrazone (CCCP) inhibition test, quantitative real-time polymerase chain reaction (RT-qPCR), carbonyl cyanide 3-chlorophenylhydrazone (CCCP) inhibition test, quantitative real-time polymerase chain reaction (RT-qPCR), multilocus sequence typing (MLST), and pulse-field gel electrophoresis (PFGE) for all triclosan-resistant isolates. Furthermore, we also investigated the effect of triclosan exposure in vitro on antibiotic susceptibility and the efflux pump encoding gene expressions of triclosan-susceptible strains via serial passage experiments. Results: Of the 200 E. coli isolates, 2.5% (n = 5) were found to be resistant to triclosan, and multidrug resistance (MDR) and cross-resistance phenotypes were noted for these triclosan-resistant strains. The triclosan-sensitive strains also exhibited MDR phenotypes, probably because of the high resistance rate to AMP, CIP, LVX, and GEN. Gly79Ala and Ala69Thr amino acid changes were observed in the triclosan-resistant strains, but these changes may not mediate resistance of E. coli to triclosan, because mutations of these two amino acids has also been detected in triclosan-susceptible strains. Moreover, except for DC8603, all other strains enhanced the efflux pumps activity. As compared with ATCC 25922, except for fabI, increased expressions were noted for all efflux pump encoding genes such as ydcV, ydcU, ydcS, ydcT, cysP, yihV, acrB, acrD, and mdfA among the studied strains with varying PFGE patterns and STs types. Unexpectedly, 5 susceptible E. coli isolates showed rapidly increasing triclosan resistance after exposure to triclosan in vitro for only 12 days, while MDR or cross-resistance phenotypes and the overexpression of efflux pump genes were recorded among these triclosan-induced resistant isolates. Conclusions: This is the first study to report that short-term triclosan exposure in vitro increases triclosan resistance in susceptible E. coli isolates. After acquiring resistance, these strains may present MDR or cross-resistance phenotypes. Moreover, triclosan resistance mainly involves the overexpression of fabI and efflux pumps in E. coli isolates.

Background

Escherichia coli has been implicated in most hospital- and community-acquired infections, including several intestinal and extraintestinal infections, urinary tract infection, and some fatal infections that develop in immunocompromised patients [1-3]. Over the past few decades, self-medication and inappropriate usage of antibiotics has contributed to the increasing drug resistance in clinical practice. Even worse, the treatment of E. coli infections has become extremely challenging because of the increasing multidrug-resistance to antibiotics [4, 5].
Triclosan, which is a broad-spectrum and highly effective antibacterial agent, can inhibit various microorganisms even at low concentrations, and be bactericidal at high concentrations [6]. In fact, it is also used for disinfecting medical equipment to prevent possible contamination [7]. Hence, triclosan plays a key role in reducing the dissemination and the spread of pathogenic bacteria across hospital and community environments.

Unfortunately, owing to its increased clinical application, the obvious levels of triclosan in various natural and engineered environments, such as soil and water, even in the body fluids of babies and adults have been reported [8-10]. Yin et al. have estimated that the average concentration of triclosan is presently 0.36 μg/L in 80% of the urine samples in China [11]. Furthermore, triclosan is considered as a “new environmental endocrine disruptor” because of its potential endocrine disrupting effects, which had an adverse effect on the human health [12]. Unfortunately, a recent study demonstrated that triclosan can spread antibiotic-resistance genes [13]. In other words, it is presumed that the long-term use of triclosan would contribute to the deposition of triclosan residue in the human urine. In addition, the widespread use of triclosan on bacterial resistance has also been suggested. As both these aspects are believed to affect the human health, but remain controversial, it is essential to gather more evidences about the effect of triclosan on drug resistance in *E. coli* isolated from urine samples [14].

Long-term exposure to triclosan promotes reduced sensitivity to triclosan in *E. coli* through extensive resistance mechanisms *in vitro* [15]. Of which, active efflux is a resistance mechanism that involves reducing the drug concentration in bacteria, whereby the efflux system pumps the intracellular antibacterial drugs out of the cell; this event confers the bacteria with resistance against a wide range of antimicrobials and biocides, including triclosan [16, 17]. Indeed, several drug efflux pumps are known to mediate resistance to traditional antibiotics and biocides, including the resistance nodulation division (RND) family, the major facilitator superfamily (MFS), the small multi-resistance (SMR), and the multidrug and toxic compound extrusion (MATE) families [18]. In addition, *fabI* mutation also contributes to *E. coli* resistance to triclosan [19]. However, the role of different types of efflux pumps is not well understood in triclosan-resistant *E. coli* isolated from urine samples.

It is important to conduct further research to yield a better scientific theoretical basis for the rational use of triclosan and toward nosocomial infection control. Our study describes the resistance profile of *E. coli* isolated from urine samples, warranting further investigation of the action mechanism of triclosan as well as its molecular epidemiology characteristics.

**Methods**

**Bacterial strains and identification**

A total of 200 non-repetitive *E. coli* strains isolated from the urine samples of urinary tract infection (UTI) patients admitted to the Affiliated Hospital of Wenzhou Medical University in Wenzhou, China in 2018 were collected. The isolates were identified by using the Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS; bioMérieux, Lyons, France).
Minimum inhibitory concentrations of triclosan

We measured the MICs of triclosan in accordance with a previous study; isolates with MICs \( \geq \text{MIC}_{90} \) (the concentration required to inhibit growth by 90% isolates; \( \text{MIC}_{90} = 0.5 \mu g/mL \)) were considered to be resistant [20]. *E. coli* ATCC 25922 was used as the quality control strain.

Antimicrobial susceptibility test

A total of 200 *E. coli* isolates were subjected to antimicrobial susceptibility testing for 10 clinical conventional antibiotics by the agar dilution method, such as ampicillin (AMP), ciprofloxacin (CIP), levofloxacin (LVX), cefepime (FEP), ceftazidime (CAZ), ertapenem (ETP), imipenem (IPM), gentamicin (GEN), nitrofurantoin (NIT), and tobramycin (TOB). Our results were interpreted by the latest guidelines from the Clinical and Laboratory Standards Institute (CLSI).

Detection of *fabI* mutation by PCR

Genome DNA of triclosan-resistant *E. coli* strains as well as randomly selected equal numbers of triclosan-susceptible strains were extracted by using the Biospin Bacterial Genomic DNA Extraction Kit (Bioflux, Tokyo, Japan) in accordance with the manufacturer's instructions. Then, *fabI* was amplified by PCR with specific oligonucleotide primers, and the positive PCR products were directly sequenced by the Shanghai Genomics Institute Technology Co. Ltd [17]. Next, gene mutations were further analyzed according to the GenBank accession number NC000913.3 of the *E. coli* genome assembly used in the BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) comparisons [21]. Moreover, 14 known drug efflux pump encoding genes (*ydcT*, *ydcU*, *ydcV*, *ydcS*, *cysP*, *cysU*, *marA*, *soxS*, *yhiv*, *acrB*, *acrD*, *acrF*, *mdfA*, and *norE*) were also amplified with the RT-qPCR primers in order to ensure that the strain carried the gene for subsequent RT-qPCR experiments. The PCR and RT-qPCR primers used are listed in the Supplementary Table S1 (see Additional File 1).

Efflux pump inhibition test

To test the efflux pump activity of triclosan-resistant *E. coli* strains, efflux pump inhibitor CCCP was tested. The resistant strains were tested on agar plates without or with 10 \( \mu g/mL \) CCCP by the agar dilution method. Compared with for triclosan alone, the MICs value of triclosan combination with 10 \( \mu g/mL \) CCCP decreased to \( \geq 4 \), which confirmed a positive inhibitory effect [22]. In addition, the concentration of 10 \( \mu g/mL \) was determined as the optimal sub-minimum inhibitory concentrations (sub-MICs) that could inhibit the overexpression of efflux pump without affecting the growth of bacteria using the agar dilution method.

Expression levels of efflux pumps by RT-qPCR

In addition to detecting the *fabI* expression, 14 efflux pump encoding genes were also examined by RT-qPCR, which included the ABC transporters system encoding the genes *ydcT, ydcU, ydcV, ydcS, cysP*, and
cysU, the Arac-regulator genes marA and soxS; the RND efflux pump encoding genes yhiv and acrBDF; the MdfA efflux TolC encoding genes mdfA; and the NorE efflux pump encoding gene norE.

Briefly, triclosan-resistant strains with an active efflux pump were also tested, while ATCC 25922 served as the control strain. The abovementioned strains were also inoculated in fresh Luria broth (LB) and allowed to grow to the logarithmic phase (OD$_{600}$ = 0.6). The total cellular RNA of these cultures was extracted by using the Bacterial RNA Miniprep Kit (Biomiga, Shanghai, China) according to the manufacturer's recommendation. Subsequently, the purified RNA was reverse transcribed into cDNA via the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, MA, USA) and amplified by using the TB Green Premix Ex Taq II (Tli RNaseH Plus) (2×) (Takara, Japan). In the PCR reaction, a global gene gapA and the housekeeping gene 16S rRNA were used as the corresponding internal controls, and the quantification of efflux pump genes was performed by the $2^{\Delta\Delta Ct}$ method. An expression of $\geq 2$ in comparison with that of the control strain ATCC 25922 indicated an upregulation, which is in accordance with a previous report [21]. Specific RT-qPCR primers are listed in the Supplementary Table S1 (see Additional file 1). All experiments were performed in at least 3 biological replicates, and the data were expressed as the mean ± SD (Supplementary Table S2; see Additional file 1).

**Genotyping by MLST**

All triclosan non-susceptible isolates were typed using the MLST method. The sequences of 8 housekeeping genes (trpB, uidA, dinB, icdA, pabB, polB, put, and trpA) were amplified with specific primers available at the MLST database (https://bigsdb.pasteur.fr/index.html), and the sequence types (STs) were evaluated in comparison with the allelic profiles to the MLST database [23].

**Strain-typing PFGE**

To confirm and analyze the clonal relatedness among the triclosan-resistant isolates, PFGE was performed in accordance with the PulseNet protocols published by the US Centers for Disease Control and Prevention (CDC) with some minor modifications. Briefly, the cell suspensions were treated with protease K and incubated with the XbaI restriction enzyme for at least 2 h at 37°C to digest the DNA fragments. Then, PFGE was performed using the CHEF-MAPPER XA PFG system (Bio-Rad, USA) for 18 h. The detailed running condition were as follows: initial switch time value of 2.16 s and a final switch time of 54.17 s at a gradient of 6 V/cm at a 120° included angle [24]. Next, the electrophoretic banding patterns were visualized by the GelDoc XR gel imaging system (Bio-Rad, USA) and further analyzed by Quantity One (Bio-Rad Laboratories, USA). The Unweighted Pair Group Method with Arithmatic Mean (UPGMA) with optimization set at 1.5% to create the dendrogram at the cut-off line $\geq 85\%$ was considered to analyze the genetic relatedness [25]. The standard Salmonella strain H9812 was considered as the positive control.

**Serial passage experiment**
In order to determine whether triclosan exposure in vitro increased the bacterial resistance, as previously described, serial passage experiment was conducted for triclosan-susceptible isolates DC8361, DC8363, DC8400, DC8413, and DC8510 [26]. Specifically, the isolates were cultivated on Macconkey agar plate and cultured overnight at 37°C to obtain a single isogenic strain, which was then inoculated into 3-mL fresh LB broth with different concentrations of triclosan at 37°C for overnight, and the ticlosan gradient concentrations were 0.0625, 0.125, 0.25, 1, 2, 4, 8, 16, 32, 64, and 128 µg/mL. Culture supernatants with bacterial growth in the highest triclosan concentrations were aspirated and continuously passaged in fresh triclosan gradients, and after only 12 days of triclosan exposure, triclosan-mutant strains with MICs ≥32 µg/mL were obtained.

Next, the stability of triclosan resistance was confirmed via continuous passage in vitro. Briefly, the triclosan-mutant strains were cultured in 3-mL fresh LB broth without triclosan at 37°C for 24 h. Every 24 h, 30 µL of overnight culture supernatants were transferred to another 5-mL tube containing 2.97-mL of fresh LB broth without triclosan. After 12 days, the MICs of triclosan and antibiotics and the expression levels of efflux pump genes were tested in triplicate, respectively, using the same method described previously.

**Results**

**The MICs of triclosan and antibiotics**

Only 5 triclosan-resistant isolates were selected (2.5%, 5/200), with triclosan MICs 0.03125-8 µg/mL, and a low triclosan-tolerance rate of *E. coli* was recorded from the urine specimens (Table 1). Interestingly, these triclosan-resistant isolates tended to be resistant to multiple antibacterial agents, including AMP, FEP, CAZ, and GEN. The resistance profiles shown in Figure 1, all 200 *E. coli* isolates showed susceptibility to ETP and IPM, and most of the *E. coli* isolates were also susceptible to FEP, CAZ, NIT, and TOB, but resistant to AMP, CIP, LVX, and GEN, with the resistance rate of 81.5%, 57%, 53.5%, and 34%, respectively, suggesting that triclosan-sensitive strains may also exhibit multiple-resistant phenotypes. To explore the relationship between triclosan exposure and MDR phenotypes, further serial passage experiment are warranted.

**Triclosan-induced isolates with reduced susceptibility to triclosan presented MDR or cross-resistance phenotypes after short-term triclosan exposure in vitro**

Stable triclosan-induced strains with reduced susceptibility to triclosan were grown under triclosan pressure via serial passaging. The MICs of triclosan and the tested antibiotics for the parent and induced strains are shown in Table 2. After exposure to a subinhibitory concentration of triclosan in vitro for only 12 days, the derived triclosan-resistant strains emerged immediately, and the MICs of triclosan increased by 256-512 times. Notably, triclosan-induced strains showed a slight decrease in susceptibility to IPM and NIT, but an obvious increase in resistance to CIP, LVX, FEP, and TOB. In a word, each mutant displayed intermediate or high level of resistance to at least one antibiotic, suggesting that these triclosan-resistant mutants had MDR or cross-resistance phenotypes.
Analysis of fabI mutation

PCR revealed that the fabI and 14 efflux pump encoding genes were present in all of the tested strains, except for the acrF. A variety of different mutations were detected in both the resistant and susceptible strains. In DC8419 and DC8424 strains, the Gly79Ala and Ala69Thr mutations were detected, respectively. However, these mutations were also detected in the susceptible strains. In addition, we discovered other mutations of fabI in the susceptible strains, such as Met2Arg, Ser5Leu, Val4Ser, and Asp235Glu (Table 1).

Efflux pump phenotype test

We sought to further investigate the triclosan-resistance mechanism among the resistant isolates. In compared to the absence of CCCP, the triclosan MICs of DC8358, DC8419, DC8424, and DC8724 reduced by 8, 4, 4, and 16 times in the presence of 10 μg/mL CCCP, respectively. Our results indicated that the efflux pumps systems were extremely active among the abovementioned 4 isolates. Inversely, DC8603, unlike other resistant strains, displayed a negative phenotype in the efflux pump test, which remained unaffected by the MICs of triclosan without or with CCCP (Table 3).

Expression levels of fabI and efflux pump encoding genes

The assessment of the expression levels of fabI in this study revealed >2-fold increased expression of fabI in all triclosan-resistant strains. In comparison with the triclosan-susceptible control strain ATCC 25922, the 5.69-41.85-fold-changes were noted for the fabI expression (Figure 2).

In addition, to better comprehend the relationship between triclosan resistance and the expression levels of efflux pump genes, different efflux pump types were also tested (Figure 3; Supplementary Table S2 [see Additional file 1]). Compared to that in E. coli ATCC 25922, the ydcV expression was evidently increased (>2-fold) in DC8358 (fold-changes: ydcV, 5.71 ± 0.68). Enhanced expressions of ydcV, yihV, and acrB (fold-changes: ydcV, 8.74 ± 0.61; yihV, 3.57 ± 0.52; acrB, 3.44 ± 0.21, respectively) were observed for DC8419. Similarly, the expressions of ydcU, ydcS, yihV, acrD, and mdfA (fold-changes: ydcU, 4.71 ± 0.13; ydcS, 2.8 ± 0.42; yihV, 6.82 ± 0.65; acrD, 2.63 ± 0.14; mdfA, 5.13 ± 0.26, respectively) were increased for DC8424. The upregulation of active efflux pump genes ydcT, ydcU, ydcS, cysP, and yihV (fold-changes: ydcT, 6.56 ± 0.56; ydcU, 18.25 ± 1.36; ydcS, 8.76 ± 0.49; cysP, 3.89 ± 0.2; yihV, 2.00 ± 0.03, respectively) was noted for DC8724. These results were consistent with those of the efflux pump inhibition test, which indicated that efflux pumps overactivity could induce the overexpression of efflux pump genes, which in turn mediates triclosan resistance in E. coli isolates.

Overexpression of efflux pump encoding gene mediated triclosan resistance in E. coli isolates

To better comprehend the role of efflux pumps in triclosan resistance of E. coli isolates, the expression levels of 14 efflux pump genes in 5 triclosan-susceptible strains before and after repeated exposure to sublethal concentrations of triclosan were also examined (Figure 4; Supplementary Table S3 [see Additional file 1]). At least twice-fold increase in the efflux pump encoding genes in comparison to that for the parent strain without triclosan exposure indicated overexpression [21]. Based on our results, a
significant increase in the expression of the efflux pump genes was noted in 80% of the induced isolates for \textit{marA} and \textit{yihV}, 60% of the induced isolates for \textit{norE}, \textit{ydcS}, \textit{acrB}, and \textit{mdfA}; 40% of the induced isolates for \textit{ydcT}, \textit{ydcU}, \textit{ydcV}, \textit{cysU}, \textit{soxS}, and \textit{acrD}, 20% of the induced isolates for \textit{cysP}, and 0% of the induced isolates for \textit{acrF}.

\textbf{Molecular epidemiological analysis}

PFGE analysis revealed that the similarity among these isolates was low (<0.85) owing to the large differences in their PFGE patterns. Similarly, the MLST results confirmed their categorization into multiple and scattered STs, such as ST3, ST833, ST567, ST471, and ST1 (Figure 5). Thus, the abovementioned results demonstrate that triclosan-resistant strains showed extremely low clonal relatedness in this study.

\textbf{Discussion}

The usage of disinfectants has become common in clinics and household. As a result, increasing evidences have shown the presence of the disinfecting agent, for example, triclosan in human body fluids, such as urine, which has raised health concerns. The consensus on the relationship between biocides and antimicrobial resistance is controversial, and the effect of triclosan exposure on bacterial resistance is also unestablished.

In this study, we selected 5 triclosan-resistant strains (2.5%, 5/200) from 200 \textit{E. coli} strains isolated from urine samples, and observed lower resistance rates among them in comparison to previous reports; these triclosan-resistant strains were characterized by their MDR profiles [20]. However, triclosan-sensitive clinical strains showed high rate of resistance to AMP, CIP, LVX, and GEN, which may also exhibit MDR phenotype. Obviously, triclosan-resistant strains were resistant to at least 6 types of antibiotics, indicating that the multidrug resistance rate of these strains was significantly higher than that of triclosan-sensitive strains. This fact raises the question of whether triclosan exposure affects or promotes bacterial resistance.

In our further research, we randomly selected 5 strains (DC8361, DC8363, DC8400, DC8413, and DC8510) that were sensitive to triclosan and to almost all antibiotics used in serial passage experiments, which proved that resistance developed in the selected isolates in only 12 days of triclosan exposure \textit{in vitro}. In fact, MDR or cross-resistance phenotypes were also observed in these triclosan-induced resistant isolates. Consistent with previous reports, our results also suggested that triclosan exposure could rapidly increase bacterial resistance to triclosan, which was accompanied by a decrease in susceptibility to clinically important antimicrobial agents, such as CIP and LVX, owing to cross-resistance [27, 28]. One reasonable explanation for the mechanisms of cross-resistance between triclosan and antibiotics is that triclosan inhibits a specific bacterial target in a manner similar to that of clinically relevant antibiotics. Hence, it is possible that resistance to triclosan can confer cross-resistance to other antimicrobial agents via gene mutation and efflux pump activities [29]. However, the specific mechanisms of cross-resistance between triclosan and antibiotics need further research for clarification.
Based on the obtained phenomena and previous reports, we believe that triclosan exposure contributes not only to the acquisition of triclosan resistance but also facilitates the reduction in the susceptibility to clinical antimicrobials. This notion provides sufficient evidence for avoidance of the long-term use of triclosan in clinical practice [21, 27]. Moreover, it is worth noting that significantly reduced triclosan sensitivity occurred during the serial passage experiment, which provides a meaningful guidance for the reasonable use of triclosan, including regulation of its concentration and dosage, toward the prevention of increased resistance of pathogens to triclosan.

A past study suggested that effective upregulation of the efflux pump genes plays an important role in non-susceptibility of bacteria to biocides [30]. Accordingly, we tested the activity of 4 different types of TolC and their relative expressions. Under triclosan stimulation, increased efflux pump activity of the isolates were recorded in our study. In addition, the expression levels of ABC transporters system encoding genes \(ydcT, ydcU, ydcV, ydcS\), and \(cysU\) and those of RND-type TolC encoding genes \(acrB, acrD\) and \(yihV\), and \(mdfA\), which belongs to the MFS family, was significantly increased in comparison with those of ATCC 25922; these findings are consistent with those of a previous study conducted in China [31]. In contrast to past reports, no increase in the expression levels of other efflux pump encoding genes was noted, probably indicating that ABC transport efflux pump, RND-type TolC, and MFS family activity are the relatively stronger advantages during the process of adaptive changes of the studied isolates to triclosan [17, 21]. Cumulatively, our results suggest a strong relationship between genes overexpression and increased tolerance of \(E. coli\) against triclosan, which suggests that multiple efflux pumps may synergistically mediate triclosan resistance. These findings were further confirmed through serial passage experiments, wherein the expression levels of efflux pump encoding genes among triclosan-induced strains were found to be significantly higher than those of the parent strains. In conclusion, our results suggest that the overexpression of different efflux pump mediated triclosan resistance in different \(E. coli\) strains.

Similar to that reported previously, our findings indicated 5 triclosan-resistance strains showing \(fabI\) overproduction [31]. Nevertheless, the mutation of \(fabI\) did not mediate the resistance of \(E. coli\) to triclosan in our research, which is inconsistent with other reports. This difference can be attributed to the modification in the Gly79Ala and Ala69Thr amino acids in both triclosan-resistant and -susceptible strains in our study [16, 17]. Perhaps, triclosan resistance was mediated by \(fabI\) and efflux pumps overexpression in our tested strains, rather than by \(fabI\) mutation. In addition, different pulse types and STs types were recorded in the studied isolates via PFGE and MLST, which suggests no transmission and a clonal dissemination among the tested triclosan-resistant strains.

However, our study also has a limitation. Although we could demonstrate the presence of multiple and cross-resistance between triclosan and antibiotics, the underlying mechanisms for the same remains the focus of our future research.

Conclusions
We are the first to suggest that *E. coli* isolates can acquire triclosan resistance in only 12 days under the stimulation of subinhibitory concentration of triclosan *in vitro* and that triclosan exposure can contribute to reduce the susceptibility to clinical antimicrobials, which in turn can accelerate the emergence of cross-resistance or multidrug-resistant bacteria. In addition, we also systematically described that bacteria acquire resistance to triclosan through the overexpression of *fabI* and efflux pumps. In summary, our findings emphasize that the extensive and long-term use of triclosan would warrant improved vigilance with regards to the presence and emergence of multidrug resistance in *E. coli* bacteria present in urine. Moreover, it is important to stress the rational use of triclosan as a control measure against the spread of multiple and cross-resistance.

**Abbreviations**

ATCC: American Type Cultures Collection; CLSI: Clinical and Laboratory Standards Institute; CCCP: Carbonyl cyanide 3-chlorophenylhydrazone; CDC: Centers for Disease Control and Prevention; *E. coli*: *Escherichia coli*; MICs: Minimal Inhibitory Concentrations; MDR: Multidrug-resistant; MIC₉₀: The concentration required to inhibit growth by 90% isolates; MLST: Multilocus sequence typing; MATE: The multidrug and toxic compound extrusion family; MFS: The major facilitator superfamily; LB: Luria Broth; PCR: Polymerase chain reaction; PFGE: Pulse-field gel electrophoresis; RT-qPCR: Quantitative real-time polymerase chain reaction; RND: The resistance nodulation division family; SSIs: Surgical site infections; STs: Sequence types; SMR: The small multi-resistance family; UTI: Urinary tract infection.

**Declarations**

**Acknowledgements**

Not applicable.

**Funding**

This work was financially supported by the Planned Science and Technology Project of Wenzhou (no. Y20180193). The funder had no role in the design of the study and collection, analysis, and interpretation of data and writing of the manuscript.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Ethics approval and consent to participate**

The need for ethics approval and consent is deemed unnecessary in this research according to the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author information**
Weiliang Zeng is first author.

**Affiliations**
Department of Medical Lab Science, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.

Weiliang Zeng, Yajie Zhao, Xiangkuo Zheng and Jianming Cao

Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.

Wenya Xu, Ye Xu, Wenli Liao, Chunquan Xu and Tieli Zhou

**Contributions**
WLZ, WYX, and WLL carried out experiments. WLZ and YX analyzed the data. WLZ wrote the manuscript. CQX and XKZ performed the results analysis and YJZ directed the drawing. JMC and TLZ designed the study and revised the manuscript. All authors reviewed and approved the final version of the manuscript.

**Corresponding authors**
Correspondence to Tieli zhou or Jianming Cao.

**References**
1. Raeispour M, Ranjbar R. Antibiotic resistance, virulence factors and genotyping of Uropathogenic *Escherichia coli* strains. Antimicrob Resist Infect Control. 2018;7:118-25.
2. Alanazi MQ, Alqahtani FY, Aleanizy FS. An evaluation of *E. coli* in urinary tract infection in emergency department at KAMC in Riyadh, Saudi Arabia: retrospective study. Ann Clin Microbiol Antimicrob. 2018;17(1):1-7.
3. Riley LW. Pandemic lineages of extraintestinal pathogenic *Escherichia coli*. Clin Microbiol Infect. 2014;20(5):380-90; doi: 10.1111/1469-0691.12646.
4. Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012. Antimicrobial Agents and Chemotherapy. 2016;60(5):2680-3.
5. Walker E, Lyman A, Gupta K, Mahoney MV, Snyder GM, Hirsch EB. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Clin Infect Dis. 2016;63(7):960-5.

6. Yueh MF, Tukey RH. Triclosan: A Widespread Environmental Toxicant with Many Biological Effects. Annu Rev Pharmacol Toxicol. 2016;56:251-72.

7. Arslan NC, Atasoy G, Altintas T, Terzi C. Effect of triclosan-coated sutures on surgical site infections in pilonidal disease: prospective randomized study. Int J Colorectal Dis. 2018;33(10):1445-52; doi: 10.1007/s00384-018-3138-z.

8. Pycke BF, Geer LA, Dalloul M, Abulaa O, Jenck AM, Halden RU. Human fetal exposure to triclosan and triclocarban in an urban population from Brooklyn, New York. Environ Sci Technol. 2014;48(15):8831-8.

9. Jin C, Yao Q, Zhou Y, Shi R, Gao Y, Wang C, et al. Exposure to triclosan among pregnant women in northern China: urinary concentrations, sociodemographic predictors, and seasonal variability. Environ Sci Pollut Res Int. 2020;27(5):4840-8; doi: 10.1007/s11356-019-07294-1.

10. Rolland M, Lyon-Caen S, Sakhi AK, Pin I, Sabaredzovic A, Thomsen C, et al. Exposure to phenols during pregnancy and the first year of life in a new type of couple-child cohort relying on repeated urine biospecimens. Environ Int. 2020;139:105678; doi: 10.1016/j.envint.2020.105678.

11. Yin J, Wei L, Shi Y, Zhang J, Wu Q, Shao B. Chinese population exposure to triclosan and triclocarban as measured via human urine and nails. Environ Geochem Health. 2016;38(5):1125-35.

12. Ribado JV, Ley C, Haggerty TD, Tkachenko E, Bhatt AS, Parsonnet J. Household triclosan and triclocarban effects on the infant and maternal microbiome. EMBO Molecular Medicine. 2017;9(12):1732-41.

13. Lu J, Wang Y, Zhang S, Bond P, Yuan Z, Guo J. Triclosan at environmental concentrations can enhance the spread of extracellular antibiotic resistance genes through transformation. Sci Total Environ. 2020;713:136621; doi: 10.1016/j.scitotenv.2020.136621.

14. Xue J, Wu Q, Sakthivel S, Pavithran PV, Vasukutty JR, Kannan K. Urinary levels of endocrine-disrupting chemicals, including bisphenols, bisphenol A diglycidyl ethers, benzophenones, parabens, and triclosan in obese and non-obese Indian children. Environ Res. 2015;137:120-8.

15. Henly EL DJ, Maingay JB, Lacey MM, Smith TJ, Forbes S. Biocide Exposure Induces Changes in Susceptibility, Pathogenicity, and Biofilm Formation in Uropathogenic Escherichia coli. Antimicrob Agents Chemother. 2019:e01892–18.

16. Sun Y, Hu X, Guo D, Shi C, Zhang C, Peng X, et al. Disinfectant Resistance Profiles and Biofilm Formation Capacity of Escherichia coli Isolated from Retail Chicken. Microb Drug Resist. 2019;25(5):703-11.

17. Curiao T, Marchi E, Viti C, Oggioni MR, Baquero F, Martinez JL, et al. Polymorphic variation in susceptibility and metabolism of triclosan-resistant mutants of Escherichia coli and Klebsiella pneumoniae clinical strains obtained after exposure to biocides and antibiotics. Antimicrob Agents Chemother. 2015;59(6):3413-23; doi: 10.1128/AAC.00187-15.
18. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006;19(2):382-402.

19. Khan R, Zeb A, Roy N, Thapa Magar R, Kim HJ, Lee KW, et al. Biochemical and Structural Basis of Triclosan Resistance in a Novel Enoyl-Acyl Carrier Protein Reductase. Antimicrob Agents Chemother. 2018;62(8):e00648–18.

20. Morrissey I, Oggioni MR, Knight D, Curiao T, Coque T, Kalkanci A, et al. Evaluation of epidemiological cut-off values indicates that biocide resistant subpopulations are uncommon in natural isolates of clinically-relevant microorganisms. PLoS One. 2014;9(1):e86669.

21. Sonbol FI, El-Banna TE, Abd El-Aziz AA, El-Ekhnawy E. Impact of triclosan adaptation on membrane properties, efflux and antimicrobial resistance of Escherichia coli clinical isolates. J Appl Microbiol. 2019;126(3):730-9; doi: 10.1111/jam.14158.

22. Park YK, Ko KS. Effect of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) on killing Acinetobacter baumannii by colistin. J Microbiol. 2015;53(1):53-9.

23. Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, et al. Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genomics. 2008;9:560; doi: 10.1186/1471-2164-9-560.

24. M RE, Fair MA, Gautom R, Cameron DN, Hunter SB, Swaminathan B, et al. Standardization of Pulsed-Field Gel Electrophoresis Protocols for the Subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. FOODBORNE PATHOGENS AND DISEASE. 2006 3:59-67.

25. Bi R, Kong Z, Qian H, Jiang F, Kang H, Gu B, et al. High Prevalence of bla NDM Variants Among Carbapenem-Resistant Escherichia coli in Northern Jiangsu Province, China. Front Microbiol. 2018;9:2704; doi: 10.3389/fmicb.2018.02704.

26. Lu J, Jin M, Nguyen SH, Mao L, Li J, Coin LJM, et al. Non-antibiotic antimicrobial triclosan induces multiple antibiotic resistance through genetic mutation. Environ Int. 2018;118:257-65; doi: 10.1016/j.envint.2018.06.004.

27. Kampf G. Biocidal Agents Used for Disinfection Can Enhance Antibiotic Resistance in Gram-Negative Species. Antibiotics (Basel). 2018;7(4):110-24.

28. Nicolae Dopcea G, Dopcea I, Nanu A, Diguta C, Matei F. Resistance and cross-resistance in Staphylococcus sp. after prolonged exposure to different antiseptics. J Glob Antimicrob Resist. 2019:1-19.

29. Yazdankhah SP, Scheie AA, Høiby EA, Lunestad B-T, Heir E, Fotland TØ, et al. Triclosan and antimicrobial resistance in bacteria: an overview. Microbial drug resistance (Larchmont, NY). 2006;12(2):83-90.

30. Lin F, Xu Y, Chang Y, Liu C, Jia X, Ling B. Molecular Characterization of Reduced Susceptibility to Biocides in Clinical Isolates of Acinetobacter baumannii. Front Microbiol. 2017;8:1836; doi: 10.3389/fmicb.2017.01836.

31. Li M, He Y, Sun J, Li J, Bai J, Zhang C. Chronic Exposure to an Environmentally Relevant Triclosan Concentration Induces Persistent Triclosan Resistance but Reversible Antibiotic Tolerance in
### Tables

#### Table 1 Mutations of *fabI* and MICs of triclosan and antibiotics against *E. coli* strains

| Isolates | Triclosan (μg/mL) | Antibiotic MICs a (μg/mL) | Mutations in *fabI* b |
|----------|-------------------|---------------------------|-----------------------|
|          |                   | AMP | CIP | LVX | FEP | CAZ | ETP | IPM | GEN | NIT | TOB |
| DC8358   | 8                 | >128| 0.5 | 0.5 | 32  | 16  | 16  | 2   | >64 | 64  | >64 |
| DC8419   | 4                 | >128| >32 | 64  | 16  | 16  | <0.5| <0.25| >64 | 32  | 32  |
| DC8424   | 4                 | >128| >32 | 16  | >64 | >64 | >32 | >32 | >64 | 64  | >64 |
| DC8603   | 2                 | >128| >32 | >64 | 64  | 32  | <0.5| <0.25| <2  | >128| <2  |
| DC8724   | 8                 | >128| >32 | 32  | 32  | 64  | 16  | >64 | 16  | >64 |
| DC8361   | 0.125             | <4  | <0.25| 0.5 | <1  | <2  | <0.5| <0.25| <2  | 16  | <2  |
| DC8363   | 0.125             | >128| <0.25| 0.5 | 2   | <2  | <0.5| <0.25| <2  | <8  | <2  |
| DC8400   | 0.125             | >128| <0.25| <0.25| <1 | <2  | <0.5| <0.25| <2  | 16  | <2  |
| DC8413   | 0.25              | >128| <0.25| <0.25| <1 | <2  | <0.5| <0.25| <2  | <8  | <2  |
| DC8510   | 0.125             | >128| <0.25| <0.25| <2 | <2  | <0.5| <0.25| <2  | <8  | <2  |

a MICs, Minimum inhibitory concentration. AMP, ampicillin; CIP, ciprofloxacin; LVX, levofloxacin; FEP, cefepime; CAZ, ceftazidime; ETP, ertapenem; IPM, imipenem; GEN, gentamicin; NIT, nitrofurantoin; TOB, tobramycin. b Gly, Glicine; Ala, Alanine; Thr, Threonine; Met, Methionine; Arg, Arginine; Val, Valine; Phe, Phenylalanine; Ser, Serine; Leu, Leucine; Asp, aspartic acid; Glu, glutamic acid. c The values in bold font indicate resistance. d ND, Not detected.
| Isolates | DC8361 | DC8363 | DC8400 | DC8413 | DC8510 |
|----------|--------|--------|--------|--------|--------|
| TCS      |        |        |        |        |        |
| Pre 0.125| 0.125  | 0.125  | 0.125  | 0.125  | 0.125  |
| Post 32  | 32     | 64     | 128    | 128    | 32     |
| AMP      | <4     | <4     | >128   | >128   | >128   |
| CIP      | <0.25  | <0.25  | <0.25  | <0.25  | 1      |
|          | <0.25  | 2      | <0.25  | <0.25  | <0.25  |
| LVX      | 0.5    | 0.5    | 0.5    | 0.5    | 2      |
| FEP      | <1     | <1     | 2      | 4*     | <1     |
|          | <1     | <1     | <1     | <1     | 1*     |
| CAZ      | <2     | <2     | <2     | <2     | <2     |
| ETP      | <0.5   | <0.5   | <0.5   | <0.5   | <0.5   |
| IPM      | <0.25  | <0.25  | <0.25  | <0.25  | 1      |
| GEN      | <2     | <2     | <2     | <2     | <2     |
| NIT      | 16     | 32     | 16     | 16     | 16     |
| TOB      | <2     | 8*     | <2     | <2     | <2     |

a Pre, wild-type strains; b Post, mutant strains; C MICs, Minimum inhibitory concentration; TCS, triclosan; AMP, ampicillin; CIP, ciprofloxacin; LVX, levofloxacin; FEP, cefepime; CAZ, ceftazidime; ETP, ertapenem; IPM, imipenem; GEN, gentamicin; NIT, nitrofurantoin; TOB, tobramycin; d The values in bold font indicates resistance; * intermediate.

Table 3 Efflux pump phenotype test
| Isolates | MICs (μg/mL) | fold changes | Efflux pump phenotype* |
|----------|--------------|--------------|------------------------|
|          | Triclosan   | Triclosan + CCCP (10 μg/mL) |                     |
| DC8358   | 8           | 1            | 8                      | +                      |
| DC8419   | 4           | 1            | 4                      | +                      |
| DC8424   | 4           | 1            | 4                      | +                      |
| DC8603   | 2           | 2            | 1                      | -                      |
| DC8724   | 8           | 0.5          | 16                     | +                      |

*Compared with triclosan alone, the MICs value of triclosan decreased ≥4 was confirmed to have an inhibitory effect when triclosan was used in combination with 10 μg/mL CCCP. + indicates the strains with positive efflux pump phenotype. - indicates the strains with negative efflux pump phenotype.

**Figures**
Figure 1

Triclosan susceptibility and antimicrobial resistance profile TCS, triclosan; AMP, ampicillin; CIP, ciprofloxacin; LVX, levofloxacin; FEP, cefepime; CAZ, ceftazidime; ETP, ertapenem; IPM, imipenem; GEN, gentamicin; NIT, nitrofurantoin; TOB, tobramycin.
Relative fabI expression level

The values of three biological repeats represent the mean ± SD. *indicates the gene overexpression, which is the relative expression level increased by 2-fold or greater in comparison with that of the control strain E. coli ATCC 25922. In comparison to ATCC 25922, the fabI expression was increased (>2-fold) in DC8358 (fold-changes: 5.69 ± 0.49), DC8419 (fold-changes: 25.14 ± 0.42), DC8424 (fold-changes: 5.11 ± 0.43), DC8603 (fold-changes: 34.05 ± 0.23), and DC8724 (fold-changes: 41.85 ± 0.59).

Figure 2
Figure 3

Relative gene expression levels (A) The relative expression levels of efflux pump encoding genes in DC8358, the expression of ydcV (fold-changes: ydcV, 5.71 ± 0.68) was increased; (B) The relative expression levels of efflux pump encoding genes in DC8419, the expression of ydcV, yihV, and acrB (fold-changes: ydcV, 8.74 ± 0.61; yihV, 3.57 ± 0.52; acrB, 3.44 ± 0.21, respectively) was increased; (C) The relative expression levels of efflux pump encoding genes in DC8424, the expression of ydcU, ydcS, yihV, acrD, and mdfA (fold-changes: ydcU, 4.71 ± 0.13; ydcS, 2.8 ± 0.42; yihV, 6.82 ± 0.65; acrD, 2.63 ± 0.14; mdfA, 5.13 ± 0.26, respectively) was increased; (D) The relative expression levels of efflux pump encoding genes in DC8724, the expression of ydcT, ydcU, ydcS, cysP, and yihV (fold-changes: ydcT, 6.56 ± 0.56; ydcU, 18.25 ± 1.36; ydcS, 8.76 ± 0.49; cysP, 3.89 ± 0.2; yihV, 2.00 ± 0.03, respectively) was increased. The values of three biological repeats represent the mean ± SD. *indicates the gene overexpression, which is the relative expression level increased by 2-fold or greater in comparison to that of the control strain ATCC 25922.
Figure 4

Relative gene expression levels in the parent strains and the induced strains A-E. The expression levels of 14 efflux pump encoding genes among DC8361 and DC8361-R, DC8363 and DC8363-R, DC8400 and DC8400-R, DC8413 and DC8413-R, and DC8510 and DC8510-R. -R indicates triclosan-induced strains; *indicates the relative expression levels increased by 2-fold or greater in comparison with those of the parent strains. The values of three biological repeats represent the mean ± SD.

Figure 5

PFGE and MLST profiles of triclosan-resistant E. coli isolates. The relatedness of PFGE results was analyzed using the QualityOne software (Bio-Rad Laboratories, USA), and the phylogenetic tree was
generated using the UPGMA clustering. The cut-off line $\geq 85\%$ was considered to analyze genetic relatedness. The result show differences in the PFGE patterns and STs typing.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1revised.doc